

# Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/C3882F935477EN.html>

Date: April 2022

Pages: 127

Price: US\$ 2,000.00 (Single User License)

ID: C3882F935477EN

## Abstracts

Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cough - Drugs In Development, 2022, provides an overview of the Cough (Respiratory) pipeline landscape.

Cough is a reflex action that clears the throat of mucus or foreign irritants. Signs and symptoms include stuffy nose, hoarseness, wheezing and shortness of breath and heartburn or a sour taste in mouth. Risk factors include laryngopharyngeal reflux, allergies, reduced hydration, smoking, asthma, chronic bronchitis, gastroesophageal reflux and chemical sensitivities. Treatment for cough includes antihistamines, decongestants, antibiotics and cough suppressants.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cough - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cough (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 2, 9, 6, 1, 13, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory).

The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Cough - Overview

Cough - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cough - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cough - Companies Involved in Therapeutics Development

Cough - Drug Profiles

Cough - Dormant Projects

Cough - Discontinued Products

Cough - Product Development Milestones

Featured News & Press Releases

Mar 29, 2022: Aldeyra Therapeutics to announce top-line data for systemic RASP modulator ADX-629 at 2022 Research & Development Day

Mar 22, 2022: Trevi Therapeutics hosting key opinion leader webinar on the seriousness of chronic cough in Idiopathic Pulmonary Fibrosis (IPF)

Mar 16, 2022: Trevi ends enrolment early in Phase II IPF chronic cough trial after positive interim data

Feb 24, 2022: Trevi Therapeutics reports statistically significant result on interim analysis from the Ph2 CANAL trial of Nalbuphine ER in the treatment of chronic cough in idiopathic pulmonary fibrosis

Feb 04, 2022: Algernon Pharmaceuticals announces completion of enrollment in its Phase 2 study of Ifenprodil for IPF and chronic cough

Jan 24, 2022: Merck provides U.S. and Japan regulatory update for Gefapixant

Jan 20, 2022: MSD obtained manufacturing and marketing approval for Rifunua tablets, the world's first selective P2X3 receptor antagonist for chronic cough.

Jan 17, 2022: Algernon receives positive FDA feedback on Phase IIb chronic cough trial

Dec 28, 2021: Hansoh Pharmaceutical Group Company announces clinical trial notice of HS-10383 tablets

Dec 21, 2021: Sino Biopharmaceutical : Innovative medicine “TCR1672” obtained approval for clinical trial

Dec 13, 2021: BELLUS Health announces positive topline results from its phase 2b SOOTHE trial of BLU-5937 for the treatment of refractory chronic cough

Dec 02, 2021: Algernon Pharmaceuticals projects full enrollment for phase 2 IPF and chronic cough trial

Nov 01, 2021: BELLUS Health convenes virtual analyst event to discuss the chronic cough landscape and its selective P2X3 antagonist BLU-5937

Oct 21, 2021: Axalbion treats first subjects in phase II chronic cough treatment trial

Oct 08, 2021: Sino Biopharmaceutical announces IND application of innovative medicine “TCR1672” filed with and accepted by FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Cough, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Companies, 2022 (Contd..1)  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Companies, 2022 (Contd..2)  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Cough - Pipeline by Adare Pharma Solutions, 2022  
Cough - Pipeline by AfaSci Inc, 2022  
Cough - Pipeline by Aldeyra Therapeutics Inc, 2022  
Cough - Pipeline by Algernon Pharmaceuticals Inc, 2022  
Cough - Pipeline by Antheia Inc, 2022  
Cough - Pipeline by Asana BioSciences LLC, 2022  
Cough - Pipeline by Axalbion SA, 2022  
Cough - Pipeline by Beijing Tide Pharmaceutical Co Ltd, 2022  
Cough - Pipeline by BELLUS Health Inc, 2022  
Cough - Pipeline by Charleston Laboratories Inc, 2022  
Cough - Pipeline by Chiesi Farmaceutici SpA, 2022  
Cough - Pipeline by Conrig Pharma ApS, 2022  
Cough - Pipeline by Evotec SE, 2022  
Cough - Pipeline by Future Analgesics, 2022  
Cough - Pipeline by Grunenthal GmbH, 2022  
Cough - Pipeline by Hyundai Pharma Co Ltd, 2022  
Cough - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2022  
Cough - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022  
Cough - Pipeline by Korea United Pharm Inc, 2022  
Cough - Pipeline by Merck & Co Inc, 2022  
Cough - Pipeline by NeRRe Therapeutics Ltd, 2022  
Cough - Pipeline by Nippon Chemiphar Co Ltd, 2022  
Cough - Pipeline by Nocion Therapeutics Inc, 2022

Cough - Pipeline by Nuformix Plc, 2022  
Cough - Pipeline by PhytoHealth Corp, 2022  
Cough - Pipeline by Shionogi & Co Ltd, 2022  
Cough - Pipeline by Sino Biopharmaceutical Ltd, 2022  
Cough - Pipeline by SiteOne Therapeutics Inc, 2022  
Cough - Pipeline by SolAeroMed Inc, 2022  
Cough - Pipeline by Trevi Therapeutics Inc, 2022  
Cough - Pipeline by Tris Pharma Inc, 2022  
Cough - Pipeline by Whan In Pharm Co Ltd, 2022  
Cough - Pipeline by Wuhan LL Science and Technology Development Co Ltd, 2022  
Cough - Dormant Projects, 2022  
Cough - Dormant Projects, 2022 (Contd..1)  
Cough - Dormant Projects, 2022 (Contd..2)  
Cough - Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

- Number of Products under Development for Cough, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022

## I would like to order

Product name: Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/C3882F935477EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C3882F935477EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

